AIDX
20/20 Biolabs, Inc.
Next earnings ≈ Aug 19, 2026 · est. from filing cadence
Last earnings -3.7% on 2026-05-20
$0.60
▲ +1.58%$0.60▼ -97.49%
over 1Y
L $0.57EODHDH $23.85
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.6%
1W-1.6%
1M-38.1%
3M-66.7%
YTD-97.5%
1Y-97.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Revenue grew 16.7% YoY; but unprofitable (net margin -182.8%).
Revenue (FY2025) $2.05M · FY2025
20/20 Biolabs, Inc. shows $2.05M in FY2025 revenue (+16.7% YoY), a -182.8% net margin, and 19447.7% ROE.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | $1.75M | $2.05M |
| Gross profit | $360K | $605K |
| Operating income | -$5.68M | -$3.33M |
| Net income | -$5.55M | -$3.74M |
| Diluted EPS | -$1.16 | -$0.76 |
| Net margin | -316.8% | -182.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.24M
EV / EBITDA—
EV / Sales2.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-59.7%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$1.03M
Altman Z-Score-12.80 distress
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-15). Worth a closer look.
Recent filings
all on EDGAR ↗DEFA14AFiling2026-06-23open ↗DEF 14APeriod ending 2026-08-182026-06-23open ↗PRE 14APeriod ending 2026-06-012026-06-01open ↗8-KPeriod ending 2026-05-192026-05-26open ↗424B3Filing2026-05-21open ↗424B3Filing2026-05-21open ↗10-QPeriod ending 2026-03-312026-05-20open ↗8-KPeriod ending 2026-05-202026-05-20open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗424B3Filing2026-04-28open ↗424B3Filing2026-04-28open ↗8-KPeriod ending 2026-04-232026-04-28open ↗
Frequently asked
- Is 20/20 Biolabs, Inc. (AIDX) a buy?
- AIDX currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 16.7% YoY; but unprofitable (net margin -182.8%).
- What is 20/20 Biolabs, Inc.'s quality score?
- AIDX scores 47.05882352941176/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001139685, latest 10-Q filed 2026-05-20) · EODHD · as of 6/23/2026, 12:42:02 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.